Development of a 3D spheroid system of primary human hepatocytes that supports efficient HBV infection
S. Xu,H. Yang,M. Yu,R. Brocket,X. Xie,L. Gamelin,J. Chia,G. Lee,I. Mikaelian,V. Barry,W. Delaney,G. Cheng,R. Muench
DOI: https://doi.org/10.1111/jvh.02_12935
2018-01-01
Journal of Viral Hepatitis
Abstract:daily entecavir (ETV). Viral DNA, RNA and antigen knockdown were measured [qHBsAg, HB corerelated antigen (qHBcrAg) in all, qHBeAg in HBeAgpos]. Serum HBV RNA was quantitated using a highthroughput assay on the Abbott m2000 system with a limit of quantitation of 45 U/mL (where 1 U of HBV RNA = 1 IU HBV DNA) and by the Van Boemmel method (Hepatology, 2015). Results: The Abbott HBV RNA assay showed good selectivity. After initiation of ETV plus ARC, HBV RNA showed no correlation with rapidly decreasing HBV DNA. A good correlation with the Van Boemmel assay was seen above the LLOQ (r2=0.88) but the new test had increased sensitivity. In HBeAgpos, HBV RNA correlated well with qHBsAg (r2=0.86), qHBeAg (r2=0.85), and qHBcrAg (r2=0.90), all of which showed large reductions during therapy and followup. This was the case regardless of whether antigen reductions were observed in direct response to ARC or offtherapy, possibly due to sustained host virologic control. In HBeAgneg CHB, no correlation between measurable qHBsAg or qHBcrAg and HBV RNA was observed, despite one CHB achieving HBsAg seroclearance. No viral products were detectable in this patient post seroclearance. Conclusions: (1) The Abbott HBV RNA assay showed good selectivity for HBV RNA, higher sensitivity and a good correlation with the Van Boemmel assay. (2) In HBeAgpos CHB, HBV RNA correlated well with quantitative serum antigens, consistent with the mode of action of ARC. (3) In HBeAgneg CHB, no correlation of HBV RNA with serum antigens was observed. Possible reasons could be differences in sensitivity between the assays, design of the HBV RNA assay, or a disproportionate effect of ARC on HBcrAg, which is exclusively derived from cccDNA, while not affecting total mRNA levels in HBeAgneg CHB. 4) Studies with the novel RNAi therapy AROHBV, designed to suppress viral RNA from all sources could further elucidate the role of serum markers in CHB management. References: Van Bommel, F., Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, Edelmann A. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015 Jan;61(1):66–76. Disclosure of Interest: E. Butler: None Declared, D. Wong: None Declared, K. Jackson: None Declared, T. Schluep Shareholder of: Arrowhead Pharmaceuticals, Employee of: Arrowhead Pharmaceuticals, J. Gersch: None Declared, M. Kuhns: None Declared, G. Cloherty: None Declared, S. Locarnini: None Declared, M.F. Yuen: None Declared. LBO-03 | Developmentofa3Dspheroid systemofprimaryhumanhepatocytesthat supportsefficientHBVinfection S Xu; H Yang; M Yu; R Brocket; X Xie; L Gamelin; J Chia; G Lee; I Mikaelian; V Barry; W Delaney; G Cheng; R Muench Biology, GILEAD SCIENCES, INC, Foster City, United States